[go: up one dir, main page]

CR6613A - ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO - Google Patents

ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO

Info

Publication number
CR6613A
CR6613A CR6613A CR6613A CR6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A
Authority
CR
Costa Rica
Prior art keywords
expression
adsss
genesis
live
changing
Prior art date
Application number
CR6613A
Other languages
English (en)
Inventor
A Conrad Charles
Chen Yin
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of CR6613A publication Critical patent/CR6613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un metodo para alterar la expresion de una secuencia de acido nucleico objetivo en una celula objetivo mediante la produccion de ADNc de una sola cadena (ADNC-ss) en la celula objetivo in vivo.
CR6613A 1999-10-04 2002-04-03 ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO CR6613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41156899A 1999-10-04 1999-10-04
US51470700A 2000-02-28 2000-02-28

Publications (1)

Publication Number Publication Date
CR6613A true CR6613A (es) 2004-04-21

Family

ID=27021437

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6613A CR6613A (es) 1999-10-04 2002-04-03 ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO

Country Status (11)

Country Link
EP (1) EP1222259A1 (es)
JP (1) JP2003511025A (es)
KR (1) KR20020059608A (es)
CN (1) CN1276083C (es)
AU (1) AU7855300A (es)
BR (1) BR0014814A (es)
CA (1) CA2386246A1 (es)
CR (1) CR6613A (es)
IL (1) IL148946A0 (es)
MX (1) MXPA02003422A (es)
WO (1) WO2001025419A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419964B2 (en) * 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
WO2002034951A2 (en) 2000-10-23 2002-05-02 Gen-Probe Incorporated Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
WO2003052071A2 (en) * 2001-12-14 2003-06-26 Yale University Intracellular generation of single-stranded dna
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
EP1802754A2 (en) * 2004-09-28 2007-07-04 CytoGenix, Inc. Single-stranded antimicrobial oligonucleotides and uses thereof
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN102154269B (zh) * 2011-01-06 2012-05-23 湖南农业大学 基于pcr的串联重复序列快速构建法和专用引物对及应用
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CN108396043A (zh) * 2017-02-06 2018-08-14 中国科学院上海应用物理研究所 一种5`端磷酸化单链dna的制备方法及其应用
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
EP3873537A4 (en) * 2018-11-02 2022-10-12 Nikegen Limited RECOMBINANT PARVOVIRUS VECTORS AND METHODS FOR THEIR PRODUCTION AND USE
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
CN116286979A (zh) * 2023-03-07 2023-06-23 长沙忠健科技有限公司 一种表达逆转录酶和rna序列的质粒、细胞及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022114A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. PRODUCTION OF ssDNA $i(IN VIVO)
EP1117776A1 (en) * 1998-10-09 2001-07-25 Ingene, Inc. ENZYMATIC SYNTHESIS OF ssDNA

Also Published As

Publication number Publication date
JP2003511025A (ja) 2003-03-25
BR0014814A (pt) 2002-09-17
CN1399679A (zh) 2003-02-26
KR20020059608A (ko) 2002-07-13
AU7855300A (en) 2001-05-10
CN1276083C (zh) 2006-09-20
MXPA02003422A (es) 2004-09-10
WO2001025419A1 (en) 2001-04-12
EP1222259A1 (en) 2002-07-17
IL148946A0 (en) 2002-09-12
CA2386246A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
CR6613A (es) ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO
AR046846A2 (es) Acido 3-hidroxipropionico y otros compuestos organicos
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
AR024318A1 (es) Moleculas de acido nucleico del trigo, celulas de plantas transgenicas y plantas y el uso de las mismas para la produccion de almidon modificado.
ES2182897T3 (es) Regulacion por proteasoma de la actividad de nf-kappa-b.
CY1108896T1 (el) ΔΙΠΛΟΚΛΩΝΟ RNA (dsRNA) ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΤΗΣ ΕΚΦΡΑΣΗΣ ΠΡΟΚΑΘΟΡΙΣΜΕΝΟΥ ΓΟΝΙΔΙΟΥ
AR027600A1 (es) Polipeptidos que tienen actividad de alfa-amilasa alcalina y los acidos nucleicos que lo codifican
AR023230A1 (es) Polipeptidos mutantes con actividad de alfa-amilasa alcalina y usos de dichos polipeptidos.
ES2175753T3 (es) Injerto biosintetico y metodo para su produccion.
AR030513A1 (es) Plantas transgenicas que contienen senuelos moleculares que alteran el contenido proteico en las mismas.
ES2061720T3 (es) Transformacion de tejido vegetal.
EP2816117A3 (en) Collagen producing plants and methods of generating and using same
ATE335852T1 (de) Happier mapping
ES2059498T3 (es) Procedimiento para la produccion de avermectina b y cultivos para ello.
DK0972445T3 (da) Kimærisk mus som udtrykker et humant antistof
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
CR9164A (es) Estabilizacion de esteres de glucocorticoides con acidos
BR0212227B1 (pt) Agente e processos para desbaste de frutas, bem como seu emprego
BR9813099A (pt) Seleção positiva-negativa na recombinação homóloga
NO20020949L (no) Fettsyredesaturasegen fra planter
ES2157690T3 (es) Metodo de producir el nivel de potencia recibido en una estacion base de una red cdma y estacion base para su ejecucion.
AR069074A1 (es) Modificacion de biosintesis de lignina por supresion con acido nucleico sentido
UA94613C2 (ru) Модифицированный фермент dmo и трансгенное растение, которое его продуцирует
ES2192669T3 (es) Uso de proteinas como agentes frente a enfermedades autoinmunes.
BR0014926A (pt) Sistema de produção de proteìna

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)